Danièle Godelaine
Scientist
Ludwig Center at Brussels
Ludwig Institute for Cancer Research
Belgium
Biography
I joined the Brussels Branch of the Ludwig Institute in 1994, working on the analysis of CTL responses in melanoma patients vaccinated with MAGE-3.A1 peptide-pulsed autologous dendritic cells. More recently I focused on the analysis of the spontaneous CTL response of non-metastatic breast carcinoma patients as a possible prognostic factor. I also participate in efforts to understand the mechanisms by which the secretory function of tumor-infiltrating lymphocytes is altered by the microenvironment.
Research Interest
Melanoma, breast cancer, tumor-immunology
Publications
-
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P. Immunity. 2008, 28:414-24
-
Petit AE, Demotte N, Scheid B, Wildmann C, Bigirimana R, Gordon-Alonso M, Carrasco J, Valitutti S, Godelaine D, van der Bruggen P. A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion. Nature Communications. 2016 Jul 22;7:12242.
